Oncotarget Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating... read more June 6, 2024
Oncotarget The Obesity Paradox, Metformin and Lung Cancer In a new editorial, researchers from Instituto Nacional de Cancerología discuss the "obesity paradox"... read more July 27, 2023
Oncotarget Trending With Impact: Analysis of Mutational Burden in NSCLC Researchers conducted a multi-site cohort study of tumor mutational burden among hundreds of patients diagnosed... read more April 21, 2022
Oncotarget New Study: ALK Rearrangement Among Lung Cancer Patients In Oncotarget’s Volume 12, Issue 23, cover paper, researchers retrospectively assessed the prevalence of... read more November 10, 2021
Oncotarget Trending With Impact: Unconventional Method Effectively Targets NSCLC In a trending paper published by Oncotarget, researchers developed a divergent strategy to treat non-small... read more September 30, 2021
Oncotarget Trending With Impact: Promising Non-Small Cell Lung Cancer Prodrug Researchers examined the preclinical prodrug LP-184 and its efficacy in treating non-small cell lung cancers... read more August 26, 2021
Oncotarget Behind the Study: Retaining Nanomolar Potency in Lung Cancer Dr. Aditya Kulkarni discusses a study he co-authored, published by Oncotarget in 2021, and entitled, “... read more August 16, 2021
Oncotarget Trending with Impact: Machine Learning Used to Compare ALK Inhibitors Researchers use a computer simulated modeling system to highlight the strengths and weaknesses of two... read more March 4, 2021
Oncotarget Trending with Impact: Novel MicroRNA Underexpressed in Lung Cancer In search of new ways to target lung cancer cells, researchers in this study demonstrated... read more February 4, 2021